Next Article in Journal
The Regulatory Role of T Cell Responses in Cardiac Remodeling Following Myocardial Infarction
Previous Article in Journal
Egg Allergy: Diagnosis and Immunotherapy
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 21
Issue 14
10.3390/ijms21145011
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Potential Hepatotoxins Found in Herbal Medicinal Products: A Systematic Review

by
Nguyen Van Quan
1,
Tran Dang Xuan
1 and
Rolf Teschke
2,*
1
Transdisciplinary Science and Engineering Program, Graduate School of Advanced Science and Engineering, Hiroshima University, Hiroshima 739-8529, Japan
2
Department of Internal Medicine II, Division of Gastroenterology and Hepatology, Klinikum Hanau, Teaching Hospital of the Medical Faculty, Goethe University Frankfurt/Main, 63450 Hanau, Germany
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(14), 5011; https://doi.org/10.3390/ijms21145011
Submission received: 12 June 2020 / Revised: 7 July 2020 / Accepted: 8 July 2020 / Published: 16 July 2020
(This article belongs to the Section Molecular Toxicology)
Browse Figures
Versions Notes

Abstract

:
The risk of liver injury associated with the use of herbal medicinal products (HMPs) is well known among physicians caring for patients under a HMP therapy, as documented in case reports or case series and evidenced by using the Roussel Uclaf Causality Assessment Method (RUCAM) to verify a causal relationship. In many cases, however, the quality of HMPs has rarely been considered regarding potential culprits such as contaminants and toxins possibly incriminated as causes for the liver injury. This review aims to comprehensively assemble details of tentative hepatotoxic contaminants and toxins found in HMPs. Based on the origin, harmful agents may be divided according two main sources, namely the phyto-hepatotoxin and the nonphyto-hepatotoxin groups. More specifically, phyto-hepatotoxins are phytochemicals or their metabolites naturally produced by plants or internally in response to plant stress conditions. In contrast, nonphyto-hepatotoxic elements may include contaminants or adulterants occurring during collection, processing and production, are the result of accumulation of toxic heavy metals by the plant itself due to soil pollutions, or represent mycotoxins, herbicidal and pesticidal residues. The phyto-hepatotoxins detected in HMPs are classified into eight major groups consisting of volatile compounds, phytotoxic proteins, glycosides, terpenoid lactones, terpenoids, alkaloids, anthraquinones, and phenolic acids. Nonphyto-hepatotoxins including metals, mycotoxins, and pesticidal and herbicidal residues and tentative mechanisms of toxicity are discussed. In conclusion, although a variety of potential toxic substances may enter the human body through HMP use, the ability of these toxins to trigger human liver injury remains largely unclear.

1. Introduction

In recent years, the topic of convincing efficacy observed along with the use of herbal medicinal products (HMPs) and the associated risk of liver injury has been of major concern among scientists, physicians, pharmacists, manufacturers, and regulators [1,2,3,4,5,6]. In the context of toxicity, the question remained regarding the source of poisons, either associated with the plant itself or related to exogenous poisons. It is undeniable that the use of HMPs has not only brought some remarkable results in medical treatment but also led to great achievements in science and economics [1]. Traditional medicines are a potential treasure derived from indigenous knowledge of using natural products to treat human diseases or improve at least minor ailments. Since ancient times, raw plants as well as refined plant products are in common use, of which, traditional Chinese medicine (TCM), Ayurveda in India, Kampo in Japan, traditional Korean medicine, and Unani in old Greece are the most outstanding ones. Recently, the discovery of new compounds from plants that can substantially contribute to alleviating several serious widespread diseases in the world merit mentioning, such as the discovery of artemisinin by Youyou Tu for therapy of malaria, and not to forget William Campbell and Satoshi Ōmura who disclosed avermectins for the treatment of helminthic diseases [1]. On the other hand, some modern therapies have been successful in concomitant use with herbal medicines [3]. However and despite of anecdotal evidence and widespread use in several countries, well-conducted randomized controlled trials (RCTs) supporting the efficacy of HMPs are largely lacking. Thus, the efficacy of herbal remedies is still unclear. Moreover, there is concern regarding the prevalent use of HMPs since the risk of use may be too high because of reported liver injury [1,3,4,5,6]. Most hepatotoxic injuries associated with the use of HMPs have been reported from herbal TCM with clear evidence for a causal relationship [3,7,8]. Although main hepatotoxic TCM plants and their ingredients have been investigated, groups of hepatotoxic phytocompounds and contaminants from other HMPs have not been adequately congregated.
In this systematic review, we classified two groups of hepatotoxic compounds and contaminants including hepatotoxic phytochemicals and nonphyto-hepatotoxins found in HMPs. The MEDLINE/PubMed database was used to follow the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and searched for key terms.

2. Methodology and Search Strategy

The principles of PRISMA were used for this systematic review article (Figure 1). For literature search, the search terms included hepatotoxic medicinal plants; herbal medicine induced liver injury; hepatotoxic natural compounds; phytochemicals induced liver injuries in order to preliminarily determine the medicinal plant species and toxic components. The targeted compounds and contaminants were then searched for together with each of the terms hepatotoxicity, liver injury, and liver failure to confirm the toxic property by using the same database. A total of 242 scientific publications were screened and filtered. Eventually, 117 publications were selected as the core dataset, all of which were cited in this review. The selective search was based principally on English language reports from 1920 to May 30, 2020 by reputable publishers.

3. Phyto-Hepatotoxins from HMPs

The term “phyto-hepatotoxins” in this review implies any potential hepatotoxic compound synthesized by medicinal plants, which may be regulated by the plant’s intrinsic genomics or be influenced by extrinsic factors during plant’s life. A number of phytochemicals have been identified with benefits for human health including hepatoprotective effects [9], but more liver injury cases induced by phytocompounds have been reported with increasing frequency. A list of potentially hepatotoxic compounds found in some commonly used HMPs is provided for a quick overview with added references that also proposed indications of treatment, although therapeutic efficacy has rarely been verified by RCTs (Table 1).
Eight main phytochemical groups with potential hepatotoxicity are listed (Table 1) with focus on volatiles compounds, phytotoxic proteins, glycosides, terpenoid lactones, terpenoids, alkaloids, anthraquinones, phenolic acids. Most of them are secondary metabolites produced with the aim to protect medicinal plants (MPs) from outside attacks to allow a longstanding plant survival. Apparently, secondary compounds of HMPs are cornerstones for known or assumed medicinal and pharmaceutical properties. Nevertheless, besides the potential beneficial effects, the parallel existence of toxic compounds in such products may induce unexpected adverse effects. Recently, overall 296 phytochemicals have been reported causing liver injury, of which alkaloids and terpenoids are the two major groups of hepatotoxicity [104]. In the present analysis, besides those two groups, we found that some representatives of volatile compounds, proteins, glycosides, saponins, glycoside-saponin compounds, terpenoid lactones, anthraquinones, or even several phenolic compounds also possess the potential hepatotoxicity (Table 1).
The toxicity of volatile compounds from most traditional herbal medicines is commonly believed to vanish by degrading due to high temperatures during the decoction preparation process, conditions that do not apply to pennyroyal oil, which has a long historical use as a dangerous abortifacient and as a means to induce menstruation, with pulegone as its major compound to be classified as a strong hepatotoxin [11,12]. Instead, the number of toxic proteins from commonly used MPs is likely low.
Glycosides, saponins, and glycoside-saponin compounds have increasingly been viewed as toxic chemicals in reports on liver toxicity. Kaurene, atractyloside, carboxyatractyloside, and 4′-desulphate-atractyloside are known poisonous glycosides causing liver injury, found in medicinal plants such as Xanthium strumarium and Callilepis laureola [20,21,22,23,24]. Besides, cycasin from cycad plants was early recognized to cause experimental hepatic injuries such as toxic hepatitis and cirrhosis in nonhuman primates [25,26]. Saponin compounds and their derivatives have been linked to toxic hepatitis and were identified in various MP species consisting of Albizia julibrissin, Dumasia truncata, Anemarrhena asphodeloides, Melia azedarach, Tripterygium wilfordii [22,23,24,25,26,27,28,29,30,31,32,33,34,35]. In this context, monodesmosyl saponin 3-O-α-l-rhamnopyranosyl-(1→3)-β-d-glucuronopyranosyl-28-O-β-d-glucopyranosyl oleanolic acid from Dumasia truncata showed the most remarkable toxicity toward liver cells [29].
Hepatotoxic effect of terpenoids and terpenoid lactones has been reported in association with the use of several MPs. Among toxic terpenoids, triptolide from Tripterygium wilfordii, toosendanin from Melia toosendan, lantadenes A and B from Lanata camra are the most frequently reported compounds capable of inducing liver injury. By in vitro and in vivo assays, terpenoid lactones found in Dioscorea bulbifera, Helenium aromaticum, Telekia speciosa, Aucklandia lappa, and Inula helenium have been shown to be involved in the stimulation of glutathione peroxidase activity and reduction of glutathione levels which in turn may trigger the initiation and progress of liver injury [43,44,45,46,47,48,49,50,51,52,53].
The most potent hepatotoxic anthraquinones have been identified in two species of Polygonum genus, namely P. multiflorum and P. cuspidatum. The toxicity of this compound group is seemingly associated with the suppression of bile acids transporters and activation of mitochondrial apoptosis pathway [104]. In addition, the hepatocyte apoptosis caused by anthraquinones has been linked to oxidative stress [105].
Switching from toxic to more beneficial ingredients, phenolic compounds and phyto-metabolites with phenolic-based structure have commonly been assumed as beneficial for human health, although liver injuries by phenolics have rarely been reported. As an example, phenolic acids and catechins containing gallic acid moieties from green tea Camellia sinensis are viewed as hepatotoxins, if derived from green tea extracts, and via the mechanisms of mitochondrial membrane potential collapse and reactive oxygen species (ROS) formation [90]. The causality assessment used the Roussel Uclaf Causality Assessment Method (RUCAM) as outlined in our previous reports, confirming increased risks of liver injury after consumption of green tea extracts [92,106]. Among other MPs, the hepatotoxicity of eugenol, methyleugenol, and acetyleugenol have been well documented [104]. The major mechanism of their toxicity is attributed to reduced hepatic glutathione levels using experimental mouse models. Other phyto-hepatotoxic compounds containing benzene ring have been identified in Larrea tridentata, Sassafras albidum, and Guatteria gaumeri comprising nordihydroguaiaretic acid, safrole, and α-asarone, respectively.
Among the many hepatotoxic substances, the pyrrolizidine alkaloids (PAs) have been thoroughly scrutinized regarding mechanistic steps and clinical consequences. Interestingly, hepatotoxic PAs are found in various MPs used as medicine. Among these is comfrey (Symphytum species), a PA containing herbal plant that is used for the treatment of inflammatory conditions such gout, arthritis, thrombophlebitis, skin wounds (bruises, fungal infections, ulcers, fractures, strains), varicose veins, oral lesions (gargle), bronchitis, allergies, gastritis, gastroduodenal ulcers, and diarrhea in Western Europe [59]. The hepatic problems induced by PAs were first revealed in 1920 by a study of Wilmot and Robertson, who described liver cirrhosis as a senecio disease associated with the ingestion of Senecio species in South Africa [107]. To date, a diverse number of PA-induced liver injuries has been reported, in which the most toxic PAs are identified as macrocyclic diesters of retronecine, heliotridine, and otonecine (Figure 2) [108].
The general mechanism of PAs and other phytocompounds inducing liver injury can be explained by oxidative stress, apoptosis, and abnormality of bile acid metabolism pathways (Figure 3 and Figure 4). Most of these hypotheses were derived from experimental studies using animal models simulating liver injury by PAs in patients who used herbs containing PAs and experienced hepatic sinusoidal obstruction syndrome (HSOS).
Within the oxidative stress mechanism, phyto-hepatotoxins are first metabolized by CYP450 and generate an active intermediate, which diminish hepatic GSH levels and cause mitochondrial dysfunction, resulting in overproduction of ROS (Figure 3). Subsequently, ROS leads to activation of signaling events including Nrf2-mediated activation of genes containing antioxidant response element (ARE). Nrf2 nuclear translocation and the Nrf2-mediated antioxidant defense system contribute to preventing excessive ROS levels from accumulating at the cellular and tissue levels [109].
The mechanism of hepatocyte apoptosis relating to phyto-hepatotoxins is outlined graphically and is still hypothetical (Figure 4). In short, apoptosis results from the activation of either death executioner caspase-3 or -7 which is the consequence of a chain of complex signaling transmission and metabolism by both extrinsic (by death-inducing signal complex) and intrinsic (by mitochondrial dysfunction) pathways through an agent factor like phyto-hepatotoxins.
On the other consideration, bile acids are indispensable signaling molecules, playing an important role in regulating its own homoeostasis as well as adjusting cholesterol and lipid homoeostasis [110]. The imbalance or dysfunction of bile acid content in the body may lead to hepatic problems. Previous studies found an obvious evidence between the usage of MPs containing PAs and liver injuries via the impaired metabolism of bile acids [109]. Particularly, increased serum bile acids could be a sensitive index of hepatic function caused by PAs [111]. Xiong et al. [112] found that the detoxification process of senecionine as a typical macrocyclic PA was obstructed leading to enhanced hepatic bile acids accumulation and caused injury. On the other hand, bile acids are also toxic to liver cells, and their regulation is occasionally considered as a sensitive biomarker for assessing some forms of liver injury. Therefore, further studies on other phyto-hepatotoxins associated with bile acids homeostasis should be implemented to clarify the unknown mechanism of HMPs-induced hepatotoxicity.
Clearly, liver injury by herbal products can be caused by toxic phytochemicals (Table 1) to be differentiated from those chemicals that are contaminants rather than ingredients of these products, representing nonphyto-hepatotoxins.

4. Nonphyto-Hepatotoxins from HMPs

The term “nonphyto-hepatotoxins” stands for substances and agents thatinduce liver injury and are contaminated to HMPs but not synthesized by MPs. The impurity of HMPs can be caused by biotic and/or abiotic factors with the possible contamination of dust, pollens, insects, rodents, parasites, microbes, fungi, moulds, toxins, heavy metals, pesticides, herbicides and undeclared chemicals [7,113,114]. Based on published reports we divide these contaminants into three main groups including metals, mycotoxins, as well as pesticidal and herbicidal residues (Table 2).
Metals are available in soil and water, therefore they can be absorbed by and accumulated inplants through the nutrient metabolism process. As a consequence, medicinal plants grown in a place with high concentration of metals may have a high risk of metal contamination and accumulation. Besides, HMPs can be polluted with toxic metals through pesticide and herbicide products as well as via transportation and preservation processes. The most common toxic metals detected in HMPs are arsenic, mercury, cadmium, nickel and lead [115,116]. Early studies indicated the poisonous impact of heavy metals overload on the human liver, which initiates the pathogenesis of oxidative stress to hepatocytes, metabolism dysfunction, and eventually liver injury [115,117]. Later studies have observed the similar phenomenon [1,7,118].
HMPs are also poisoned by biological factors including bacteria, fungi, yeast, and parasites with their spores and some toxins, which can easily cause misunderstandings about the actual advantage of some medicinal herbs. Among reported toxic elements, mycotoxins, a group of toxic secondary metabolites, which are primarily produced by Aspergillus, Penicillium, Fusarium, Claviceps, and Alternaria fungi. The mycotoxins most damaging the human health are aflatoxins, ochratoxin A, fumonisins, zearalenone, and deoxynivalenol [121]. Contamination with these poisons has been recognized in various HMPs during their agricultural and manufacturing processes. The hepatotoxic effects of mycotoxin mixtures were proved comprising hepatic total antioxidant capacity decrease, lipid peroxidation increase, and potential hepatic apoptosis by upregulation of the apoptotic genes Caspase-3 and Bax [120]. In the case of kava, Piper methysticum, aflatoxins contaminated the medicinal plant due to hot and humid weather conditions are considered potential culprits of kava hepatotoxicity [78,122,132].
The third group of contaminants in HMPs relate to pesticidal and herbicidal residues. It is recognized that the superior effects of synthetic herbicides and pesticides areon crop protection and agricultural production. However, overuse of these synthetic substances may have a long influence on environmental pollution and human health issues. The reported liver effects of pesticide and herbicide residues include hepatocellular hypertrophy and cytoplasm degeneration, obstructive cholestasis, decreased acetylcholinesterase activity, and hepatic mitochondrial toxicity [114,123,124,125,126,127,128,129,130,131].
A condensed hypothesis of mechanisms leading to liver injury by nonphyto-hepatotoxins is illustrated (Figure 5). Accordingly, the absorption of nonphyto-hepatotoxins by the liver may lead to increased ROS production and lysosomal fragility. Under the oxidative stress, macromolecules as proteins and DNA in hepatocytes are damaged and lipid peroxidation processes rise. The dysfunction of subcellular organelles including lysosomes and changes of hepatocytes with their mitochondria and plasma membranes are considered of particular relevance in causing liver injury (Figure 5).

5. Critical Analysis and Reality Check

Liver injury by herbs [133,134] and drugs [135] can best be assessed for causality by RUCAM [136,137]. HILI in patients consuming herbal products is a particular clinical challenge as evidenced by the large number of HILI cases [133,134] published using RUCAM for causality assessment with details provided for worldwide published 12,068 HILI cases [133] that included 11,160 HILI cases published by authors from Asia [134]. These figures were much lower compared with those of the RUCAM based 46,266 DILI cases published from 2014 up to early 2019 [135]. The analyses of RUCAM based HILI and DILI cases revealed that most case data were of good quality ready for appropriate causality assessment [133,134,135]. Authors from around the world commonly used RUCAM for their cases smoothly and without discussing any problems during its application. In a few HILI cases presented in an extra list, causality for several herbs, initially implicated in suspected HILI by regulatory agencies from Germany or the US, could not be verified using RUCAM [133,134]. Among the RUCAM based DILI cases, most received a probable or highly probable causality level [135]. However, published were also DILI cases with a possible or excluded causality grading for the implicated drug, mostly due to incomplete data or if cohorts were assessed retrospectively not allowing for prospective collection of complete important data relevant for assessment by RUCAM [135], Indeed, high causality gradings are achieved with complete data provided by prospective studies as strongly recommended by the updated RUCAM [137].
RUCAM in its original version published in 1993 [136] and as update reported in 2016 [137] represent sophisticated diagnostic algorithms [136,137,138,139] based on principles of artificial intelligence (AI) as outlined in a recent editorial [140]. In more detail, AI principles recommend the use of algorithms for solving complex processes, done for the complex multifaceted DILI and HILI by constructing RUCAM as an intelligent algorithm [136,137]. In order to simplify complex processes, the principle was to provide tools enabling input of data into a black box that systematically evaluates incoming data and fosters output of clear results such as diagnosis in complex diseases. Clearly defined elements of HILI and DILI case features with a scoring system are the bases and components of the intelligent RUCAM algorithm, prepared for receiving case data and providing a final score of probability for any herb or drug implicated in suspected HILI or DILI.
RUCAM is viewed as cornerstone assessing global causality in HILI and DILI cases. Conditions in the context of HILI are more complicated due to confounding variables because causality evaluation is confined to the whole herbal product with all ingredients and does not allow for causality evaluation of individual toxins [133,134]. This provides uncertainty to what extent individual toxins are in reality responsible for the liver injury. A variety of other causative aspects are poorly investigated, among these are adulterations of HM by conventional drugs added by manufacturers to increase product efficacy [113] and not to forget misidentified herbs included in HMPs instead of desired authentic herbs.
Additional concerns focus on the abundant indications as published and proposed for many therapeutic indications that are more than fragile and claimed on the base of data derived from in vitro data preferentially involving antioxidant properties. Finally, the issue remains concerning the efficacy of HMPs for disease treatment, heavily disputed among Western physicians and traditional herbalists as evidence base criteria were not applied in most trials and randomized controlled trials (RCTs) of good quality were rarely published. This obviously leads to the crucial point of the efficacy to risk balance which is negative for most HMPs. Potential hepatotoxic properties of the phyto-hepatotoxins and the nonphyto-hepatotoxins contained in HMPs call for regulatory product standardization and manufactural compound purification of herbal remedies.
In fact, several HMPs have been banned and/or have had warning letters issued by regulatory agencies due to their assumed toxic effects on human health. However, most reports seemingly favor the listing of herbal products associated with various toxicities in general rather than the compounds with hepatotoxicity potency in particular. For instance, the Medicines and Healthcare Products Regulatory Agency of the UK published a list of banned and restricted herbal ingredients [141] but did not mention any specific toxin as well as its adverse effect on liver. Fleischer, Su and Lin indicated that among 300 commonly used Traditional Chinese Medicines (TCMs), Ma Huang (Ephedra sinica) was the only herbal product banned by six countries including the USA, the UK, Germany, Israel, Canada and Australia [142]. The Canadian government issued the highest number of banned Chinese herbs (98 species) while the USA was found to have the least restricted ones (9 products) [142]. In the same manner, this report did not provide any information of corresponding hepatotoxins either. Additionally, the easy accessibility of HMPs on internet markets is currently causing difficulty for the surveillance and management by governmental regulators. This suggests that a global standard regulation should be established for more strictly tracking the use of HMPs to avoid the risk of liver injuries by hepatotoxins constituted in HMPs as mentioned in this review. Besides the considerations about accepted amounts of hepatotoxins, the acutely toxic chemicals as ricin, paraquat, or arsenicshould be accurately detected and completely removed from HMPs by advanced techniques with high sensitivity to assure the quality and safety of HMPs.

6. Conclusions

HILI cases caused by modern or traditional HMPs including herbal TCMs are challenging if it comes to causality assessment of possible toxins as part of the herbal products. Indeed, there are difficulties assigning toxins as causative agents in most of the published HILI cases. In addition, genetics of individuals make them to patients susceptible to rare liver injury but individual risk factors are poorly assessed. Although a variety of potentially toxic substances may enter the human body through HMP use, the relevance of their property to trigger human liver injury remains unclear in many cases. By this review, potential hepatotoxins can be found in herbal medicinal products with both types of plant originated compounds (phyto-hepatotoxins) and exogenous contaminants (nonphyto-hepatotoxins). Although potential hepatotoxins and their toxicity have been reported, the actual form of liver injury such as acute hepatocellular injury, acute cholestatic injury, mixed injury, sinusoidal obstruction syndrome, vanishing bile duct syndrome, and acute liver failure need to be further elaborated by prospective clinical investigations. Quality evaluation of HMPproducts are urgently required prior to treating patients. The composition and content of potential hepatotoxins included in HMPs must be properly assessed for the risk of liver injury during the treatment. Novel advanced kits that can quickly detect and quantify hepatotoxins in HMPs should be developed with sensors dedicated to organic and inorganic toxins. Moreover, together with the rapid development of digital technology, the combination of RUCAM, artificial intelligence (AI), and available data sources of potential hepatotoxins like those presented in this review may help discover and establish the optimal HMP therapeutics without major risks of liver injury.

Funding

This research received no external funding.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

CYP450Cytochrome P450
DILIDrug induced liver injury
GSHGlutathione
HILIHerb induced liver injury
HMPHerbal medicinal product
HSOSHepatic sinusoidal obstruction syndrome
MPMedicinal plant
PAPyrrolizidine alkaloid
RCTRandomized controlled trial
ROSReactive oxygen species
RUCAMRoussel Uclaf Causality Assessment Method
TCMTraditional Chinese medicine

References

  1. Frenzel, C.; Teschke, R. Herbal hepatotoxicity: Clinical characteristics and listing compilation. Int. J. Mol. Sci. 2016, 17, 588–625. [Google Scholar] [CrossRef] [PubMed]
  2. Yuan, H.; Ma, Q.; Ye, L.; Piao, G. The traditional medicine and modern medicine from natural products. Molecules 2016, 21, 559–576. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Ma, X.; Peng, J.H.; Hu, Y.Y. Chinese herbal medicine-induced injury. J. Clin. Transl. Hepatol. 2014, 2, 170–175. [Google Scholar] [PubMed] [Green Version]
  4. Teschke, R.; Eickhoff, A.; Wolff, A.; Xuan, T.D. Liver injury from herbs and “dietary supplements”: Highlights of a literature review from 2015 to 2017. Curr. Pharm. Rep. 2018, 4, 120–131. [Google Scholar] [CrossRef]
  5. Teschke, R.; Sarris, J.; Schweitzer, I. Kava hepatotoxicity in traditional and modern use: The presumed Pacific kava paradox hypothesis revisited. Br. J. Clin. Pharm. 2012, 73, 170–174. [Google Scholar] [CrossRef] [Green Version]
  6. Jamkhande, P.G.; Tolsarwad, G.S.; Tidke, P.S. Herbal hepatotoxicity: A review on phytochemical induced liver injury. J. Appl. Pharm. Sci. 2013, 3, 106–110. [Google Scholar]
  7. Teschke, R.; Zhang, L.; Long, H.; Schwarzenboeck, A.; Schmidt-Taenzer, W.; Genthner, A.; Wolff, A.; Frenzel, C.; Schulze, J.; Eickhoff, A. Traditional Chinese medicine and herbal hepatotoxicity: A tabular compilation of reported cases. Ann. Hepatol. 2015, 14, 7–19. [Google Scholar] [CrossRef]
  8. Melchart, D.; Hager, S.; Albrecht, S.; Dai, J.; Weidenhammer, W.; Teschke, R. Herbal traditional Chinese medicine and suspected liver injury: A prospective study. World J. Hepatol. 2017, 9, 1141–1157. [Google Scholar] [CrossRef]
  9. Domitrović, R.; Potočnjak, I. A comprehensive overview of hepatoprotective natural compounds: Mechanism of action and clinical perspectives. Arch. Toxicol. 2016, 90, 39–79. [Google Scholar] [CrossRef]
  10. Yun, C.; Jung, Y.; Chun, W.; Yang, B.; Ryu, J.; Lim, C.; Kim, J.-H.; Kim, H.; Cho, S.-I. Anti-inflammatory effects of Artemisia leaf extract in mice with contact dermatitis in vitro and in vivo. Mediat. Inflamm. 2016, 2016, 1–8. [Google Scholar] [CrossRef] [Green Version]
  11. Sullivan, J.B.; Rumack, B.H.; Thomas, H.; Peterson, R.G.; Bryson, P. Pennyroyal oil poisoning and hepatotoxicity. JAMA 1979, 242, 2873–2874. [Google Scholar] [CrossRef] [PubMed]
  12. Gordon, W.P.; Huitric, A.C.; Seth, C.L.; McClanahan, R.H.; Nelson, S.D. The metabolism of the abortifacient terpene, (R)-(+)-pulegone, to a proximate toxin, menthofuran. Drug Metab. Dispos. 1987, 15, 589–594. [Google Scholar] [PubMed]
  13. Audi, J.; Belson, M.; Patel, M.; Schier, J.; Osterloh, J. Ricin poisoning. JAMA 2005, 294, 2342–2351. [Google Scholar] [CrossRef] [PubMed]
  14. Marwat, S.K.; Rehman, F.; Khan, E.A.; Baloch, M.S.; Sadiq, M.; Ullah, I.; Javaria, S.; Shaheen, S. Review—Ricinus communis—Ethnomedicinal uses and pharmacological activities. Pak. J. Pharm. Sci. 2017, 30, 1815–1827. [Google Scholar] [PubMed]
  15. Narula, P. Abrin poisoning in an 18-month-old child. Am. J. Case Rep. 2015, 16, 146–148. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Chen, H.Y.; Foo, L.Y.; Loke, W.K. Abrin and ricin: Understanding their toxicity, diagnosis, and treatment. In Biological Toxins and Bioterrorism; Gopalakrishnakone, P., Balali-Mood, M., Llewellyn, L., Singh, B., Eds.; Springer: Dordrecht, The Netherlands, 2015; pp. 79–102. [Google Scholar]
  17. Garaniya, N.; Bapodra, A. Ethno botanical and phytophrmacological potential of Abrus precatorius L.: A review. Asian Pac. J. Trop. Biomed. 2014, 4, 27–34. [Google Scholar] [CrossRef] [Green Version]
  18. Ekue, M.R.M.; Sinsin, B.; Eyog-Matig, O.; Finkeldey, R. Uses, traditional management, perception of variation and preferences in ackee (Blighia sapida K.D. Koenig) fruit traits in Benin: Implications for domestication and conservation. J. Ethnobiol. Ethnomed. 2010, 6, 12–25. [Google Scholar] [CrossRef] [Green Version]
  19. Blake, O.A.; Bennink, M.R.; Jackson, J.C. Ackee (Blighia sapida) hypoglycin a toxicity: Dose response assessment in laboratory rats. Food Chem. Toxicol. 2006, 44, 207–213. [Google Scholar] [CrossRef]
  20. Wang, Y.; Han, T.; Xue, L.M.; Han, P.; Zhang, Q.-Y.; Huang, B.-K.; Zhang, H.; Ming, Q.-L.; Peng, W.; Qin, L.-P. Hepatotoxicity of kaurene glycosides from Xanthium strumarium L. fruits in mice. Pharmazie 2011, 66, 445–449. [Google Scholar]
  21. Xue, L.M.; Zhang, Q.Y.; Han, P.; Jiang, Y.-P.; Yan, R.-D.; Wang, Y.; Rahman, K.; Jia, M.; Han, T.; Qin, L.-P. Hepatotoxic constituents and toxicological mechanism of Xanthium strumarium L. fruits. J. Ethnopharmacol. 2014, 152, 272–282. [Google Scholar] [CrossRef]
  22. Obatomi, D.; Bach, P. Biochemistry and toxicology of the diterpenoid glycoside atractyloside. Food Chem. Toxicol. 1998, 36, 335–346. [Google Scholar] [CrossRef]
  23. Cullen, J.M.; Stalker, M.J. Liver and biliary system. In Jubb, Kennedy & Palmer’s Pathology of Domestic Animals, 6th ed.; Maxie, M.G., Ed.; Saunders Ltd.: St. Louis, MO, USA, 2015; Volume 2, pp. 258–352. [Google Scholar]
  24. Barceloux, D.G. Impila, pine thistle, and atractyloside. In Medical Toxicology of Natural Substances: Foods, Fungi, Medicinal Herbs, Plants, and Venomous Animals; Barceloux, D.G., Ed.; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2008; pp. 514–517. [Google Scholar]
  25. Ballhorn, D.J. Cyanogenic glycosides in nuts and seeds. In Nuts and Seeds in Health and Disease Prevention, 1st ed.; Preedy, V.R., Watson, R.R., Patel, V.B., Eds.; Academic Press: London, UK, 2011; pp. 129–136. [Google Scholar]
  26. Sieber, S.M.; Correa, P.; Dalgard, D.W.; Mclntire, K.R.; Adamson, R.H. Carcinogenicity and hepatotoxicity of cycasin and its aglycone methylazoxymethanol acetate in nonhuman primates. J. Natl. Cancer Inst. 1980, 65, 177–189. [Google Scholar] [PubMed]
  27. Ikeda, T.; Fujiwara, S.; Araki, K.; Kinjo, J.; Nohara, T.; Miyoshi, T. Cytotoxic glycosides from Albizia julibrissin. J. Nat. Prod. 1997, 60, 102–107. [Google Scholar] [CrossRef] [PubMed]
  28. Li, T.S.C. Taiwanese Native Medicinal Plants: Phytopharmacology and Therapeutic Values, 1st ed.; CRC Press: Boca Raton, FL, USA, 2006; p. 400. [Google Scholar]
  29. Kinjo, J.; Okawa, M.; Udayama, M.; Sohno, Y.; Hirakawa, T.; Shii, Y.; Nohara, T. Hepatoprotective and hepatotoxic actions of oleanolic acid-type triterpenoidal glucuronides on rat primary hepatocyte cultures. Chem. Pharm. Bull. (Tokyo) 1999, 47, 290–292. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  30. Kinjo, J.; Suyama, K.; Nohara, T. Triterpenoidal saponins from Dumasia truncata. Phytochemistry 1995, 40, 1765–1767. [Google Scholar] [CrossRef]
  31. Xie, Y.; Zhou, X.; Pei, H.; Chen, M.-C.; Sun, Z.-L.; Xue, Y.-R.; Tian, X.-T.; Huang, C.-G. Metabolism, pharmacokinetics, and hepatic disposition of xanthones and saponins on Zhimu treatments for exploratively interpreting the discrepancy between the herbal safety and timosaponin A3-induced hepatotoxicity. Acta Pharm. Sin. 2018, 39, 1923–1934. [Google Scholar] [CrossRef] [Green Version]
  32. Wang, Y.; Dan, Y.; Yang, D.; Hu, Y.; Zhang, L.; Zhang, C.; Zhu, H.; Cui, Z.; Li, M.; Liu, Y. The genus Anemarrhena Bunge: A review on ethnopharmacology, phytochemistry and pharmacology. J. Ethnopharmacol. 2014, 153, 42–60. [Google Scholar] [CrossRef]
  33. Oelrichs, P.B.; Hill, M.W.; Vallely, P.J.; MacLeod, J.K.; Molinski, T.F. Toxic tetranortriterpenes of the fruit of Melia azedarach. Phytochemistry 1983, 22, 531–534. [Google Scholar] [CrossRef]
  34. Khan, A.V.; Ahmed, Q.U.; Mir, M.R.; Shukla, I.; Khan, A.A. Antibacterial efficacy of the seed extracts of Melia azedarach against some hospital isolated human pathogenic bacterial strains. Asian Pac. J. Trop. Biomed. 2011, 1, 452–455. [Google Scholar] [CrossRef] [Green Version]
  35. Zhang, Y.; Jiang, Z.; Xue, M.; Zhang, S.; Wang, Y.; Zhang, L. Toxicogenomic analysis of the gene expression changes in rat liver after a 28-day oral Tripterygium wilfordii multiglycoside exposure. J. Ethnopharmacol. 2012, 141, 170–177. [Google Scholar] [CrossRef]
  36. Vliegenthart, A.D.B.; Wie, C.; Buckley, C.; Berends, C.; de Potter, C.M.J.; Schneemann, S.; Pozo, J.D.; Tucker, C.; Mullins, J.J.; Webb, D.J.; et al. Characterization of triptolide-induced hepatotoxicity by imaging and transcriptomics in a novel zebrafish model. Toxicol. Sci. 2017, 159, 380–391. [Google Scholar] [CrossRef] [PubMed]
  37. Ziaei, S.; Halaby, R. Immunosuppressive, anti-inflammatory and anti-cancer properties of triptolide: A mini review. Avicennaj. Phytomed. 2016, 6, 149–164. [Google Scholar]
  38. Tao, X.; Lipsky, P.E. The Chinese anti-inflammatory and immunosuppressive herbal remedy Tripterygium wilfordii Hook F. Rheum. Dis. Clin. N. Am. 2000, 26, 29–50. [Google Scholar] [CrossRef]
  39. Xie, F.; Zhang, M.; Zhang, C.F.; Wang, Z.T.; Yu, B.Y.; Kou, J.P. Anti-inflammatory and analgesic activities of ethanolic extract and two limonoids from Melia toosendan fruit. J. Ethnopharmacol. 2008, 117, 463–466. [Google Scholar] [CrossRef] [PubMed]
  40. He, Y.; Wang, J.; Liu, X.; Zhang, L.; Yi, G.; Li, C.; He, X.; Wang, P.; Jiang, H. Toosendanin inhibits hepatocellular carcinoma cells by inducing mitochondria-dependent apoptosis. Planta Med. 2010, 76, 1447–1453. [Google Scholar] [CrossRef] [Green Version]
  41. Yang, F.; Li, L.; Yang, R.; Wei, M.; Sheng, Y.; Ji, L. Identification of serum microRNAs as potential toxicological biomarkers for toosendanin-induced liver injury in mice. Phytomedicine 2019, 58, 152867. [Google Scholar] [CrossRef]
  42. Kirimuhuzya, C.; Waako, P.; Joloba, M.; Odyek, O. The anti-mycobacterial activity of Lantana camara a plant traditionally used to treat symptoms of tuberculosis in South-western Uganda. Afr. Health Sci. 2009, 9, 40–45. [Google Scholar]
  43. Shi, W.; Zhang, C.; Zhao, D.; Wang, L.; Li, P.; Li, H. Discovery of hepatotoxic equivalent combinatorial markers from Dioscorea bulbifera tuber by fingerprint-toxicity relationship modeling. Sci. Rep. 2018, 8, 462. [Google Scholar] [CrossRef]
  44. Wu, Z.T.; Li, Z.Q.; Shi, W.; Wang, L.L.; Jiang, Y.; Li, P.; Li, H.J. The crucial role of metabolic regulation in differential hepatotoxicity induced by furanoids in Dioscorea bulbifera. Chin. J. Nat. Med. 2020, 18, 57–69. [Google Scholar] [CrossRef]
  45. Wang, J.; Ji, L.; Liu, H.; Wang, Z. Study of the hepatotoxicity induced by Dioscorea bulbifera L. rhizome in mice. Biosci. Trends 2010, 4, 79–85. [Google Scholar]
  46. Guan, X.R.; Zhu, L.; Xiao, Z.G.; Zhang, Y.L.; Chen, H.B.; Yi, T. Bioactivity, toxicity and detoxification assessment of Dioscorea bulbifera L.: A comprehensive review. Phytochem. Rev. 2017, 16, 573–601. [Google Scholar] [CrossRef]
  47. Jodynis-Liebert, J.; Murias, M.; Błoszyk, E. Effect of several sesquiterpene lactones on lipid peroxidation and glutathione level. Planta Med. 1999, 65, 320–324. [Google Scholar] [CrossRef] [PubMed]
  48. Jodynis-Liebert, J.; Murias, M.; Błoszyk, E. Effect of sesquiterpene lactones on antioxidant enzymes and some drug-metabolizing enzymes in rat liver and kidney. Planta Med. 2000, 66, 199–205. [Google Scholar] [CrossRef] [PubMed]
  49. Merrill, J.C.; Kim, H.L.; Safe, S.; Murray, C.A.; Hayes, M.A. Role of glutathione in the toxicity of the sesquiterpene lactones hymenoxon and helenalin. J. Toxicol. Environ. Health 1988, 23, 159–169. [Google Scholar] [CrossRef] [PubMed]
  50. Stojakowska, A.; Galanty, A.; Malarz, J.; Michalik, M. Major terpenoids from Telekia speciosa flowers and their cytotoxic activity in vitro. Nat. Prod. Res. 2019, 33, 1804–1808. [Google Scholar] [CrossRef]
  51. Lim, S.; Lee, S.J.; Nam, K.W.; Kim, K.H.; Mar, W. Hepatoprotective effects of reynosin against thioacetamide-induced apoptosis in primary hepatocytes and mouse liver. Arch. Pharm. Res. 2013, 36, 485–494. [Google Scholar] [CrossRef]
  52. Qin, C.Z.; Lv, Q.L.; Wu, N.Y.; Cheng, L.; Chu, Y.C.; Chu, T.Y.; Hu, L.; Cheng, Y.; Zhang, X.; Zhou, H.H. Mechanism-based inhibition of alantolactone on human cytochrome P450 3A4 in vitro and activity of hepatic cytochrome P450 in mice. J. Ethnopharmacol. 2015, 168, 146–149. [Google Scholar] [CrossRef]
  53. Wang, L.; He, X.; Jin, C.; Ondieki, G. Mechanism-based inhibitors from phytomedicine: Risks of hepatotoxicity and their potential hepatotoxic substructures. Curr. Drug Metab. 2016, 17, 971–991. [Google Scholar] [CrossRef]
  54. Hassan, H.E.; Kelly, D.; Honick, M.; Shukla, S.; Ibrahim, A.; Gorelick, D.A.; Glassman, M.; McMahon, R.P.; Wehring, H.J.; Kearns, A.M.; et al. Pharmacokinetics and safety assessment of L-tetrahydropalmatine in cocaine users: A randomized, double-blind, placebo-controlled study. J. Clin. Pharm. 2017, 57, 151–160. [Google Scholar] [CrossRef] [Green Version]
  55. Wang, C.; Zhou, J.; Wang, S.; Ye, M.; Fan, G.; Zou, H.; Jiang, C. Shotgun approach based comparative proteomic analysis of levo-tetrahydropalmatine-induced apoptosis in hepatocytes. Toxicol. Lett. 2010, 194, 8–15. [Google Scholar] [CrossRef]
  56. Haller, C.A. Making a diagnosis of herbal-related toxic hepatitis. West. J. Med. 2002, 176, 39–44. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  57. Saxena, A.K.; Saxena, M. Advances in chemotherapy of malaria. In Progress in Drug Research/Fortschritte der Arzneimittelforschung/Progrès des Recherches Pharmaceutiques; Jucker, E., Ed.; Springer: Berlin, Germany, 1986; pp. 221–280. [Google Scholar]
  58. Tang, W.; Eisenbrand, G. Dichroa febrifuga Lour. In Chinese Drugs of Plant Origin-Chemistry, Pharmacology, and Use in Traditional and Modern Medicine; Tang, W., Ed.; Springer: Berlin, Germany, 1992; pp. 455–457. [Google Scholar]
  59. Barceloux, D.G. Comfrey and other pyrrolizidine-containing plants. In Medical Toxicology of Natural Substances: Foods, Fungi, Medicinal Herbs, Plants, and Venomous Animals; Barceloux, D.G., Ed.; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2008; pp. 449–457. [Google Scholar]
  60. Culvenor, C.C.J.; Edgar, J.A.; Jago, M.V.; Outteridge, A.; Peterson, J.E.; Smith, L.W. Hepato- and pneumotoxicity of pyrrolizidine alkaloids and derivatives in relation to molecular structure. Chem. Biol. Interact. 1976, 12, 299–324. [Google Scholar] [CrossRef]
  61. Schoental, R. Hepatotoxic activity of retrorsine, senkirkine and hydroxysenkirkine in newborn rats, and the role of epoxides in carcinogenesis by pyrrolizidine alkaloids and aflatoxins. Nature 1970, 227, 401–402. [Google Scholar] [CrossRef] [PubMed]
  62. Jiang, Z.; Liu, F.; Goh, J.J.L.; Yu, L.; Li, S.F.Y.; Ong, E.S.; Ong, C.N. Determination of senkirkine and senecionine in Tussilago farfara using microwave-assisted extraction and pressurized hot water extraction with liquid chromatography tandem mass spectrometry. Talanta 2009, 79, 539–546. [Google Scholar] [CrossRef] [PubMed]
  63. Nedelcheva, A.; Kostova, N.; Sidjimov, A. Pyrrolizidine alkaloids in Tussilago farfara from Bulgaria. Biotechnol. Biotechnol. Equip. 2015, 29, S1–S7. [Google Scholar] [CrossRef] [Green Version]
  64. Copple, B.L.; Ganey, P.E.; Roth, R.A. Liver inflammation during monocrotaline hepatotoxicity. Toxicology 2003, 190, 155–169. [Google Scholar] [CrossRef]
  65. Roeder, E. Medicinal plants in Europe containing pyrrolizidine alkaloids. Pharmazie 1995, 50, 83–98. [Google Scholar]
  66. Kumana, C.R.; Ng, M.; Lin, H.J.; Ko, W.; Wu, P.C.; Todd, D. Herbal tea induced hepatic veno-occlusive disease: Quantification of toxic alkaloid exposure in adults. Gut 1985, 26, 101–104. [Google Scholar] [CrossRef] [Green Version]
  67. Steenkamp, V.; Stewart, M.J.; Zuckerman, M. Clinical and analytical aspects of pyrrolizidine poisoning caused by South African traditional medicines. Drug Monit. 2000, 22, 302–306. [Google Scholar] [CrossRef]
  68. Wuilloud, J.C.A.; Gratz, S.R.; Gamble, B.M.; Wolnik, K.A. Simultaneous analysis of hepatotoxic pyrrolizidine alkaloids and N-oxides in comfrey root by LC-ion trap mass spectrometry. Analyst 2004, 129, 150. [Google Scholar] [CrossRef]
  69. Arseculeratne, S.N.; Gunatilaka, A.A.L.; Panabokke, R.G. Studies on medicinal plants of Sri Lanka: Occurrence of pyrrolizidine alkaloids and hepatotoxic properties in some traditional medicinal herbs. J. Ethnopharmacol. 1981, 4, 159–177. [Google Scholar] [CrossRef]
  70. Rode, D. Comfrey toxicity revisited. Trends Pharm. Sci. 2002, 23, 497–499. [Google Scholar] [CrossRef]
  71. Barceloux, D.G. Coltsfoot (Tussilago farfara L.). In Medical Toxicology of Natural Substances: Foods, Fungi, Medicinal Herbs, Plants, and Venomous Animals; Barceloux, D.G., Ed.; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2008; pp. 446–448. [Google Scholar]
  72. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012. Ephedra. [Updated 2018 Feb 10]. Available online: https://www.ncbi.nlm.nih.gov/books/NBK548711/ (accessed on 25 May 2020).
  73. Barceloux, D.G. Ma Huang (Ephedra Alkaloids). In Medical Toxicology of Natural Substances: Foods, Fungi, Medicinal Herbs, Plants, and Venomous Animals; Barceloux, D.G., Ed.; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2008; pp. 545–552. [Google Scholar]
  74. Bajaj, J.; Knox, J.F.; Komorowski, R.; Saeian, K. The irony of herbal hepatitis: Ma-Huang-induced hepatotoxicity associated with compound heterozygosity for hereditary hemochromatosis. Dig. Dis. Sci. 2003, 48, 1925–1928. [Google Scholar] [CrossRef] [PubMed]
  75. Barceloux, D.G. Kava (Piper methysticum Forster). In Medical Toxicology of Natural Substances: Foods, Fungi, Medicinal Herbs, Plants, and Venomous Animals; Barceloux, D.G., Ed.; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2008; pp. 525–531. [Google Scholar]
  76. Xuan, T.D.; Fukuta, M.; Ao, C.W.; Elzaawely, A.A.; Khanh, T.D.; Tawata, S. Efficacy of extracting solvents to chemical components of kava (Piper methysticum) roots. J. Nat. Med. 2008, 62, 188–194. [Google Scholar] [CrossRef] [PubMed]
  77. Olsen, L.R.; Grillo, M.P.; Skonberg, C. Constituents in kava extracts potentially involved in hepatotoxicity: A review. Chem. Res. Toxicol. 2011, 24, 992–1002. [Google Scholar] [CrossRef]
  78. Teschke, R.; Qiu, S.X.; Xuan, T.D.; Lebot, V. Kava and kava hepatotoxicity: Requirements for novel experimental, ethnobotanical and clinical studies based on a review of the evidence. Phyther. Res. 2011, 25, 1263–1274. [Google Scholar] [CrossRef]
  79. Bilia, A.R.; Gallori, S.; Vincieri, F.F. Kava-kava and anxiety: Growing knowledge about the efficacy and safety. Life Sci. 2002, 70, 2581–2597. [Google Scholar] [CrossRef]
  80. Teschke, R. Kava hepatotoxicity: A clinical review. Ann. Hepatol. 2010, 9, 251–265. [Google Scholar] [CrossRef]
  81. Yamazaki, Y.; Hashida, H.; Arita, A.; Hamaguchi, K.; Shimura, F. High dose of commercial products of kava (Piper methysticum) markedly enhanced hepatic cytochrome P450 1A1 mRNA expression with liver enlargement in rats. Food Chem. Toxicol. 2008, 46, 3732–3738. [Google Scholar] [CrossRef]
  82. Lin, L.; Lin, H.; Zhang, M.; Ni, B.; Yin, X.; Qu, C.; Ni, J. A novel method to analyze hepatotoxic components in Polygonum multiflorum using ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry. J. Hazard Mater. 2015, 299, 249–259. [Google Scholar] [CrossRef]
  83. Dong, X.; Fu, J.; Yin, X.; Yang, C.; Ni, J. Aloe-emodin induces apoptosis in human liver HL-7702 cells through fast death pathway and the mitochondrial pathway by generating reactive oxygen species. Phyther. Res. 2017, 31, 927–936. [Google Scholar] [CrossRef] [PubMed]
  84. Dong, X.; Ni, B.; Fu, J.; Yin, X.; You, L.; Leng, X.; Liang, X.; Ni, J. Emodin induces apoptosis in human hepatocellular carcinoma HepaRG cells via the mitochondrial caspase-dependent pathway. Oncol. Rep. 2018, 40, 1985–1993. [Google Scholar] [CrossRef] [PubMed]
  85. Bounda, G.A.; Zhou, W.; Wang, D.D.; Yu, F. Rhein elicits in vitro cytotoxicity in primary human liver HL-7702 cells by inducing apoptosis through mitochondria-mediated pathway. Evid. Based Complement. Altern. Med. 2015, 2015, 1–19. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  86. Feng, Y.; Bounda, G.A. Review of clinical studies of Polygonum multiflorum Thunb. and its isolated bioactive compounds. Pharm. Res. 2015, 7, 225. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  87. Lin, L.; Yuan, F.; Liu, Y.; Zhong, M.; Xie, T.; Ni, J.; Li, H. Hepatotoxicity and mechanism study of chrysophanol-8-O-glucoside in vitro. Biomed. Pharm. 2019, 120, 109531. [Google Scholar] [CrossRef]
  88. Beuers, U.; Spengler, U.; Pape, G.R. Hepatitis after chronic abuse of senna. Lancet 1991, 337, 372–373. [Google Scholar] [CrossRef]
  89. Vanderperren, B.; Rizzo, M.; Angenot, L.; Haufroid, V.; Jadoul, M.; Hantson, P. Acute liver failure with renal impairment related to the abuse of senna anthraquinone glycosides. Ann. Pharm. 2005, 39, 1353–1357. [Google Scholar] [CrossRef]
  90. Galati, G.; Lin, A.; Sultan, A.M.; O’Brien, P.J. Cellular and in vivo hepatotoxicity caused by green tea phenolic acids and catechins. Free Radic. Biol. Med. 2006, 40, 570–580. [Google Scholar] [CrossRef]
  91. Tariq, M.; Naveed, A.; Barkat, A.K. The morphology, characteristics, and medicinal properties of Camellia sinensis tea. J. Med. Plants Res. 2010, 4, 2028–2033. [Google Scholar] [CrossRef]
  92. Teschke, R.; Xuan, T.D. How can green tea polyphenols affect drug metabolism and should we be concerned? Expert Opin. Drug Metab. Toxicol. 2019, 15, 989–991. [Google Scholar] [CrossRef]
  93. Mbaveng, A.T.; Kuete, V. Syzygium aromaticum. In Medicinal Spices and Vegetables from Africa: Therapeutic Potential against Metabolic, Inflammatory, Infectious and Systemic Diseases, 1st ed.; Kuete, V., Ed.; Academic Press: London, UK, 2017; pp. 611–625. [Google Scholar]
  94. Mizutani, T.; Satoh, K.; Nomura, H. Hepatotoxicity of eugenol and related compounds in mice depleted of glutathione: Structural requirements for toxic potency. Res. Commun. Chem. Pathol. Pharm. 1991, 73, 87–95. [Google Scholar]
  95. Mizutani, T.; Satoh, K.; Nomura, H.; Nakanishi, K. Hepatotoxicity of eugenol in mice depleted of glutathione by treatment with DL-buthionine sulfoximine. Res. Commun. Chem. Pathol. Pharm. 1991, 71, 219–230. [Google Scholar]
  96. Bodell, W. Oxidation of eugenol to form DNA adducts and 8-hydroxy-2′-deoxyguanosine: Role of quinone methide derivative in DNA adduct formation. Carcinogenesis 1998, 19, 437–443. [Google Scholar] [CrossRef] [Green Version]
  97. Suparmi, S.; Ginting, A.J.; Mariyam, S.; Wesseling, S.; Rietjens, I.M.C.M. Levels of methyleugenol and eugenol in instant herbal beverages available on the Indonesian market and related risk assessment. Food Chem. Toxicol. 2019, 125, 467–478. [Google Scholar] [CrossRef]
  98. Lambert, J.D.; Zhao, D.; Meyers, R.O.; Kuester, R.K.; Timmermann, B.N.; Dorr, R.T. Nordihydroguaiaretic acid: Hepatotoxicity and detoxification in the mouse. Toxicon 2002, 40, 1701–1708. [Google Scholar] [CrossRef]
  99. Carlson, M.; Thompson, R.D. Liquid chromatographic determination of safrole in sassafras-derived herbal products. J. AOAC Int. 1997, 80, 1023–1028. [Google Scholar] [CrossRef] [Green Version]
  100. Borchert, P.; Wislocki, P.G.; Miller, J.A.; Miller, E.C. The metabolism of the naturally occurring hepatocarcinogen safrole to 1′-hydroxysafrole and the electrophilic reactivity of 1′-acetoxysafrole. Cancer Res. 1973, 33, 575–589. [Google Scholar]
  101. Ueng, Y.F.; Hsieh, C.H.; Don, M.J.; Chi, C.-W.; Ho, L.-K. Identification of the main human cytochrome P450 enzymes involved in safrole 1′-hydroxylation. Chem. Res. Toxicol. 2004, 17, 1151–1156. [Google Scholar] [CrossRef]
  102. Chamorro, G.; Salazar, M.; Salazar, S.; Mendoza, T. Pharmacology and toxicology of Guatteria gaumeri and alpha-asarone. Rev. Investig. Clin. 1993, 45, 597–604. [Google Scholar]
  103. López, M.; Hernández, A.; Chamorro, G.; Mendoza-Figueroa, T. α-Asarone toxicity in long-term cultures of adult rat hepatocytes. Planta Med. 1993, 59, 115–120. [Google Scholar] [CrossRef]
  104. He, S.; Zhang, C.; Zhou, P.; Zhang, X.; Ye, T.; Wang, R.; Sun, G.; Sun, X. Herb-induced liver injury: Phylogenetic relationship, structure-toxicity relationship, and herb-ingredient network analysis. Int. J. Mol. Sci. 2019, 20, 3633. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  105. Dong, X.; Fu, J.; Yin, X.; Qu, C.; Yang, C.; He, H.; Ni, J. Induction of apoptosis in HepaRG cell line by aloe-emodin through generation of reactive oxygen species and the mitochondrial pathway. Cell Physiol. Biochem. 2017, 42, 685–696. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  106. Teschke, R.; Xuan, T.D. Suspected herb induced liver injury by green tea extracts: Critical review and case analysis applying RUCAM for causality assessment. Jpn. J. Gastroenterol. Hepatol 2019, 1, 1–16. [Google Scholar]
  107. Willmot, F.; Robertson, G. Senecio disease or cirrhosis of the liver due to senecio poisoning. Lancet 1920, 196, 848–849. [Google Scholar] [CrossRef] [Green Version]
  108. Fu, P.P.; Xia, Q.; Lin, G.; Chou, M.W. Pyrrolizidine alkaloids—Genotoxicity, metabolism enzymes, metabolic activation, and mechanisms. Drug Metab. Rev. 2004, 36, 1–55. [Google Scholar] [CrossRef]
  109. Xu, J.; Wang, W.; Yang, X.; Xiong, A.; Yang, L.; Wang, Z. Pyrrolizidine alkaloids: An update on their metabolism and hepatotoxicity mechanism. Liver Res. 2019, 3, 176–184. [Google Scholar] [CrossRef]
  110. Arab, J.P.; Karpen, S.J.; Dawson, P.A.; Arrese, M.; Trauner, M. Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives. Hepatology 2017, 65, 350–362. [Google Scholar] [CrossRef]
  111. Mendel, V.E.; Witt, M.R.; Gitchell, B.S.; Gribble, D.N.; Rogers, Q.R.; Segall, H.J.; Knight, H.D. Pyrrolizidine alkaloid-induced liver disease in horses: An early diagnosis. Am. J. Vet. Res. 1988, 49, 572–578. [Google Scholar]
  112. Xiong, A.; Yang, F.; Fang, L.; Yang, L.; He, Y.; Wan, Y.Y.-J.; Xu, Y.; Qi, M.; Wang, X.; Yu, K.; et al. Metabolomic and genomic evidence for compromised bile acid homeostasis by senecionine, a hepatotoxic pyrrolizidine alkaloid. Chem. Res. Toxicol. 2014, 27, 775–786. [Google Scholar] [CrossRef]
  113. Posadzki, P.; Watson, L.; Ernst, E. Contamination and adulteration of herbal medicinal products (HMPs): An overview of systematic reviews. Eur. J. Clin. Pharmacol. 2013, 69, 295–307. [Google Scholar] [CrossRef]
  114. Kosalec, I.; Cvek, J.; Tomić, S. Contaminants of medicinal herbs and herbal products. Arch. Ind. Hyg. Toxicol. 2009, 60, 485–501. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  115. Britton, R. Metal-induced hepatotoxicity. Semin. Liver Dis. 1996, 16, 3–12. [Google Scholar] [CrossRef]
  116. Maria, C.S.; Moreno, J.; Lopez-Campos, J.L. Hepatotoxicity induced by the herbicide atrazine in the rat. J. Appl. Toxicol. 1987, 7, 373–378. [Google Scholar] [CrossRef]
  117. Goering, P.L.; Barber, D.S. Hepatotoxicity of copper, iron, cadmium, and arsenic. In Comprehensive Toxicology; McQueen, C.A., Ed.; Elsevier Science: Amsterdam, The Netherlands, 2010; pp. 501–526. [Google Scholar]
  118. Elefsiniotis, I.S.; Liatsos, G.D.; Stamelakis, D.; Moulakakis, A. Case report: Mixed cholestatic/hepatocellular liver injury induced by the herbicide quizalofop-p-ethyl. Env. Health Perspect. 2007, 115, 1479–1481. [Google Scholar] [CrossRef]
  119. Genuis, S.J.; Schwalfenberg, G.; Siy, A.-K.J.; Rodushkin, I. Toxic element contamination of natural health products and pharmaceutical preparations. PLoS ONE 2012, 7, e49676. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  120. Amadi, C.; Orisakwe, O. Herb-induced liver injuries in developing nations: An update. Toxics 2018, 6, 24. [Google Scholar] [CrossRef] [Green Version]
  121. Hasanein, P.; Emamjomeh, A. Beneficial effects of natural compounds on heavy metal–induced hepatotoxicity. In Dietary Interventions in Liver Disease: Foods, Nutrients, and Dietary Supplements; Watson, R.R., Preedy, V.R., Eds.; Academic Press: London, UK, 2019; pp. 345–355. [Google Scholar]
  122. Sun, L.H.; Lei, M.; Zhang, N.Y.; Zhao, L.; Krumm, C.S.; Qi, D.S. Hepatotoxic effects of mycotoxin combinations in mice. Food Chem. Toxicol. 2014, 74, 289–293. [Google Scholar] [CrossRef] [PubMed]
  123. Ałtyn, I.; Twarużek, M. Mycotoxin contamination concerns of herbs and medicinal plants. Toxins 2020, 12, 182. [Google Scholar] [CrossRef] [Green Version]
  124. Teschke, R.; Qiu, S.X.; Lebot, V. Herbal hepatotoxicity by kava: Update on pipermethystine, flavokavain B, and mould hepatotoxins as primarily assumed culprits. Dig. Liver Dis. 2011, 43, 676–681. [Google Scholar] [CrossRef]
  125. Alarcan, J.; Waizenegger, J.; Solano, M.D.L.M.; Lichtenstein, D.; Luckert, C.; Peijnenburg, A.; Stoopen, G.; Sharma, R.P.; Kumar, V.; Marx-Stoelting, P.; et al. Hepatotoxicity of the pesticides imazalil, thiacloprid and clothianidin—Individual and mixture effects in a 28-day study in female Wistar rats. Food Chem. Toxicol. 2020, 140, 111306. [Google Scholar] [CrossRef]
  126. VoPham, T.; Bertrand, K.A.; Hart, J.E.; Laden, F.; Brooks, M.M.; Yuan, J.M.; Talbott, E.O.; Ruddell, D.; Chang, C.-C.H.; Weissfeld, J.L. Pesticide exposure and liver cancer: A review. Cancer Causes Control 2017, 28, 177–190. [Google Scholar] [CrossRef] [PubMed]
  127. Jayaraj, R.; Megha, P.; Sreedev, P. Organochlorine pesticides, their toxic effects on living organisms and their fate in the environment. Interdiscip. Toxicol. 2016, 9, 90–100. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  128. Gomes, J.; Dawodu, A.H.; Lloyd, O.; Revitt, D.M.; Anilal, S.V. Hepatic injury and disturbed amino acid metabolism in mice following prolonged exposure to organophosphorus pesticides. Hum. Exp. Toxicol. 1999, 18, 33–37. [Google Scholar] [CrossRef] [PubMed]
  129. Sagarkar, S.; Gandhi, D.; Devi, S.S.; Sakharkar, A.; Kapley, A. Atrazine exposure causes mitochondrial toxicity in liver and muscle cell lines. Indian J. Pharmacol. 2016, 48, 200–207. [Google Scholar]
  130. Kale, V.M.; Miranda, S.R.; Wilbanks, M.S.; Meyer, S.A. Comparative cytotoxicity of alachlor, acetochlor, and metolachlor herbicides in isolated rat and cryopreserved human hepatocytes. J. Biochem. Mol. Toxicol. 2008, 22, 41–50. [Google Scholar] [CrossRef]
  131. Ujowundu, C.O.; Nwaogu, L.A.; Ujowundu, F.N.; Oparaeche, N.N.; Oyarebu, A.O. Hepatotoxicity of paraquat dichloride and ameliorative effect of nutritional supplements. Biochem. Mol. Biol. J. 2018, 4, 21. [Google Scholar] [CrossRef]
  132. Teschke, R.; Sarris, J.; Lebot, V. Contaminant hepatotoxins as culprits for kava hepatotoxicity—fact or fiction? Phyther. Res. 2013, 27, 472–474. [Google Scholar] [CrossRef]
  133. Teschke, R.; Eickhoff, A.; Schulze, J.; Danan, G. Herb-induced liver injury (HILI) with 12,068 worldwide cases published with causality assessments by Roussel Uclaf Causality Assessment Method (RUCAM): An overview. Transl. Gastroenterol. Hepatol. 2020, in press. [Google Scholar]
  134. Teschke, R.; Zhu, Y.; Jing, J. Herb induced liver injury (HILI) in the Asian region and current role of RUCAM for causality assessment in 11,160 published cases. J. Clin. Transl. Hepatol. 2020, 8, 200–214. [Google Scholar] [CrossRef]
  135. Teschke, R. Idiosyncratic DILI: Analysis of 46,266 cases assessed for causality by RUCAM and published from 2014 to early 2019. Front. Pharmacol. 2019, 10, 730. [Google Scholar] [CrossRef]
  136. Danan, G.; Bénichou, C. Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries. J. Clin. Epidemiol. 1993, 46, 1323–1330. [Google Scholar] [CrossRef]
  137. Danan, G.; Teschke, R. RUCAM in drug and herb induced liver injury: The update. Int. J. Mol. Sci. 2016, 17, 14. [Google Scholar] [CrossRef] [PubMed]
  138. Danan, G.; Teschke, R. Drug-induced liver injury: Why is the Roussel Uclaf Causality Assessment Method (RUCAM) still used 25 years after its launch? Drug Saf. 2018, 41, 735–743. [Google Scholar] [CrossRef] [PubMed]
  139. Danan, G.; Teschke, R. Roussel Uclaf Causality Assessment Method for drug-induced liver injury. Front. Pharmacol. 2019, 10, 853. [Google Scholar] [CrossRef] [Green Version]
  140. Teschke, R. DILI, HILI, RUCAM algorithm, and AI, the artificial intelligence: Provocative issues, progress, and proposals. Arch. Gastroenterol Res. 2020, 1, 4–11. [Google Scholar]
  141. Guidance: Banned and Restricted Herbal Ingredients. Available online: https://www.gov.uk/government/publications/list-of-banned-or-restricted-herbal-ingredients-for-medicinal-use/banned-and-restricted-herbal-ingredients (accessed on 25 June 2020).
  142. Fleischer, T.; Su, Y.-C.; Lin, S.J.-S. How do government regulations influence the ability to practice Chinese herbal medicine in western countries. J. Ethnopharmacol. 2017, 196, 104–109. [Google Scholar] [CrossRef] [PubMed]
Ijms 21 05011 g001 550
Figure 1. PRISMA flow diagram of references included in the review.
Figure 1. PRISMA flow diagram of references included in the review.
Ijms 21 05011 g001
Ijms 21 05011 g002 550
Figure 2. General structure of pyrrolizidine alkaloids.
Figure 2. General structure of pyrrolizidine alkaloids.
Ijms 21 05011 g002
Ijms 21 05011 g003 550
Figure 3. Phyto-hepatotoxins induce liver injury through oxidative stress. The mechanic pathway is derived from a published report by Xu et al. [109].
Figure 3. Phyto-hepatotoxins induce liver injury through oxidative stress. The mechanic pathway is derived from a published report by Xu et al. [109].
Ijms 21 05011 g003
Ijms 21 05011 g004 550
Figure 4. Phyto-hepatotoxins induce extrinsic (death receptor) and intrinsic (mitochondrial) apoptotic pathways. The pathways are adapted from the report of Xu et al. [109].
Figure 4. Phyto-hepatotoxins induce extrinsic (death receptor) and intrinsic (mitochondrial) apoptotic pathways. The pathways are adapted from the report of Xu et al. [109].
Ijms 21 05011 g004
Ijms 21 05011 g005 550
Figure 5. Summarized hypothetical mechanisms of liver injury induced by nonphyto-hepatotoxins overload. Modified from a report published by Britton [115].
Figure 5. Summarized hypothetical mechanisms of liver injury induced by nonphyto-hepatotoxins overload. Modified from a report published by Britton [115].
Ijms 21 05011 g005
Table
Table 1. List of phyto-hepatotoxins found in herbal medicinal products
Table 1. List of phyto-hepatotoxins found in herbal medicinal products
Phyto-HepatotoxinsMedicinal Plants
(Common HMPs)		Claimed Treatment of MPsReferences
Volatile Compounds
Volatile oilsArtemisia argyi
(Ai Ye)		Abdominal pain, dysmenorrhoea, uterine haemorrhage, and inflammation diseases in various countries including China, Japan, and Korea[3,10]
PulegoneMentha pulegium
Hedeoma pulegioides
(Pennyroyal oil)		Menstrual discomfort, abortifacient, inflammatory diseases like chronic bronchitis, influenza, and common upper respiratory tract infections[11,12]
Phytotoxic Proteins
RicinRicinus communis
(Bi Ma Zi)		Unspecific abdominal disorders, arthritis, backache, muscle aches, schistosomiasis, chronic backache and sciatica, chronic headache, constipation, expulsion of placenta, gallbladder pain, period pain, menstrual cramps, rheumatism, sleeplessness, and insomnia[13,14]
AbrinAbrus precatorius
(Chanothi, Xiang Si Zi)		Neuromuscular disorders, epilepsy, viral infections, malaria, fertility problems, diabetes mellitus, renal insufficiency, inflammatory disorder, and autoimmune diseases[15,16,17]
Hypoglycins A and BBlighia sapida
(Ackee)		Broad range of infections causing fever, dental decay, malaria, internal haemorrhage, dysentery, burns, eye inflammation, yellow fever, constipation, cutaneous infections, whitlow and head lice[18,19]
Glycosides
KaureneXanthium strumarium
(Cocklebur, Cang Shan)
Atractylis gummifera
Callilepis laureola
(Impila, Zulu remedy)		Rhinitis, nasal sinusitis, headache, gastric ulcer, urticaria, rheumatism, arthritis, and bacterial, fungal infections[20,21,22,23,24]
Atractyloside
Carboxyatractyloside
4’-desulphate-atractylosideCallilepis laureola
(Impila, Zulu remedy)		Stomach pains and discomfort, constipation, tape worm infections, cough, induction of fertility in young women, and impotence in males
CycasinCycas revoluta
(Su Tie)		Cancer including hepatocellular carcinoma, rheumatism, impaired diuresis[25,26]
Saponins Albizia julibrissin
(He Huan Hua, He Huan Pi)		Anxiety, cancer, depression, sleep problems (insomnia), and sore throat; Mood improvement; Reduction of swelling associated with trauma[22,27]
Monodesmosyl saponin
3-O-α-l-rhamnopyranosyl-(1→3)-β-d-glucuronopyranosyl-28-O-β-d-glucopyranosyl oleanolic acid		Dumasia truncataMuscle pains[28,29,30]
TimosaponinAnemarrhena asphodeloides
(Zhi Mu)		Common cold-induced febrile disease with arthralgia, hematochezia, tidal fever and night sweats by so called Yin deficiency, bone-steaming, cough, and hemoptoe[31,32]
TetranortriterpenoidsMelia azedarach
(Bakain)		Leprosy, scrofula, rheumatism, ringworm and scabies, malaria fever, and helminthic diseases[3,33,34]
MultiglycosideTripterygium wilfordii
(Lei Gong Teng - Thunder God Vine)		Rheumatoid arthritis and other immune diseases, autoimmune and inflammatory conditions[35]
Terpenoids
TriptolideTripterygium wilfordii
(Lei Gong Teng—Thunder God Vine)		Rheumatoid arthritis and other immune diseases, autoimmune and inflammatory conditions[35,36,37,38]
ToosendaninMelia toosendan
(Chuan Lian Zi)		Stomach pains, inflammations, and ascariasis[39,40,41]
Lantadenes A and BLantana camara
(Latana oil)		Tumor and bacterial infections[6,42]
Terpenoid Lactones
8-epidiosbulbin E acetate
Diosbulbin B
Diosbulbin D		Dioscorea bulbifera
(Huang Yao Zi)		Tumors, cancers and thyroid gland diseases[43,44,45,46]
Linifolin A
Geigerinin
Helenalin
Mexicanin I		Helenium aromaticumTumors[47,48]
6α-Hydroxy-2,3-dihydroaromaticin
Asperilin
Telekin		Telekia speciosaCancer (Balkan countries, Serbia)[49,50]
Reynosin
Alantolactone
Santamarine		Aucklandia lappa
(Mu Xiang)
Inula helenium
(Xuan Fu Hua)		Anorexia, nausea and abdominal pain (Korea); Cancer, ulcers, and viral, bacterial and parasitic infections[51,52,53]
Alkaloids
Isoquinoline alkaloids Tetrahydropalmatine Stephania delavayi
Stephania sinica
(Jin Bu Huan)		Components of Jin Bu Huan (TCM) used as a sedative, antispasmodic, analgesic and decongestant [54,55,56]
Quinazolinone alkaloids
Febrifugine		Dichroa febrifuga
(Chang Shan)		Malaria[57,58]
Pyrrolizidine alkaloids
Senecionine
Amabiline
Intermedine
Lycopsamine
Supinine
Retrorsine
Senecionine
Senkirkine		Senecio jacobaea
Senecio flaccidus
Senecio scandens
Senecio vulgaris
Senecio asperum x officinale
Heliotropium lasiocarpum
Symphytum officinale
Cynoglossum officinale
Crotalaria verrucosa
Holarrhena antidysenterica
Cassia auriculata
Borago officinalis
Tussilago farfara		Inflammatory conditions such as gout, arthritis, thrombophlebitis, skin wounds (bruises, fungal infections, ulcers, fractures, strains), varicose veins, oral lesions (gargle), bronchitis, allergies, gastritis, gastroduodenal ulcers, and diarrhea bronchitis, asthma, and cough; Gastrointestinal and urinary ailments and mainly for pulmonary complaints, blood purification, especially for rheumatism and skin irritations[59,60,61,62,63,64,65,66,67,68,69,70,71]
Sympathomimetic alkaloids
Ephedrine
Pseudoephedrine
Methylephedrine
Norephedrine		Ephedra sinica
(Ma Huang)		Bronchitis and asthma[72,73,74]
Piperidine alkaloids
Flavokavain A
Flavokavain B		Piper methysticum
(Kava)		Asthma, rheumatism, urological problems, menopausal symptoms, gonorrhea, vaginitis, nocturnal incontinence, weight loss, and insomnia[4,5,75,76,77,78,79,80,81]
Anthraquinones
Free anthraquinones
Emodin
Aloe-emodin
Rhein
Physcion		Polygonum multiflorum
(He Shou Wu, Fo-Ti)
Polygonum cuspidatum
(Hu Zhang)		Tumor, bacterial infections, inflammatory diseases, HIV, renal insufficiency, diabetes mellitus, alopecia, atherosclerosis, hyperlipidemia, and neurodegenerative cardiovascular disease prevention[82,83,84,85,86]
Anthraquinone glycosides
Aloe-emodin-8-O-glucoside
Emodin-8-O-glucoside
Chrysophanol-8-O-glucoside
Rhein-8-glucoside, Physcion-8-O-glucoside
Emodin-1-O-glucoside		Polygonum multiflorum
(He Shou Wu, Fo-Ti)
Polygonum cuspidatum
(Hu Zhang)		Tumor, bacterial infections, inflammatory diseases, HIV, renal insufficiency, diabetes mellitus, alopecia, atherosclerosis, hyperlipidemia, and neurodegenerative cardiovascular disease prevention[87]
SennosidesSenna alexandrina
(Fan Xie Ye)		Constipation, gonorrhea, bronchial congestion, wounds, diarrhea, meteorism, skin diseases, dyspepsia, fever, and hemorrhoids[88,89]
Phenolic Acids
Phenolic acids and catechinsCamellia sinensisCancer and its prevention[90,91,92]
Eugenol
Methyleugenol
Acetyleugenol		Syzygium aromaticum
Zingiber officinale
Cinnamomum burmannii
Foeniculum vulgare
Piper betle
Illicium verum
Myristica fragnans		Cancer, diabetes mellitus, and bacterial, inflammatory, fungal, protozoal and thrombotic diseases (many countries)[93,94,95,96,97]
Others
Nordihydroguaiaretic acidLarrea tridentata
(Chaparral)		Tuberculosis, arthritis, and cancer[98]
SafroleSassafras albidum
(Sassafras)		Topical anesthesia, muscle relaxation, blood purification, dental disinfectant, and skin disorders, hypertension, renal disorders, cancer, syphilis, and menstrual irregularity[99,100,101]
α-AsaroneGuatteria gaumeri
(Guatteria Gaumeri, Yumel)		Treatment of hypercholesterolemia and cholelithiasis (Mexico)[102,103]
Table
Table 2. Suspected nonphyto-hepatotoxins found in herbal medicinal products
Table 2. Suspected nonphyto-hepatotoxins found in herbal medicinal products
Nonphyto-HepatotoxinsContaminated HMPsContamination PathwayToxic EffectsReferences
Metals
Lead
Mercury
Arsenic
Copper
Cadmium
Chromium
Manganese
Nickel
Zinc
Iron
Selenium
Antimony
Thallium
Tin		Sporadically detected in HMPs over the worldFrom soil, water, herbicides, pesticides or production processingOxidative stress;
Lipid peroxidation;
Lysosomal injury;
Mitochondrial dysfunction;
Hepatic DNA damage		[7,113,114,115,117,119]
Mycotoxins
Aflatoxins (AF)
Ochratoxin A (OTA)
Fumonisins (FB)
Zearalenone (ZEN)
Deoxynivalenol (DON)		Ayurveda from India and traditional
Chinese medicines, European and American herbal remedies, South Pacific medicinal plants (kava)		From Aspergillus, Penicillium, Fusarium, Claviceps, and Alternaria fungi during the storage conditions and processing of HMPs Hepatic total antioxidant capacity decline;
Lipid peroxidation increase;
Potential hepatic apoptosis by upregulation of the apoptotic genes Caspase-3 and Bax		[78,120,121,122]
Pesticidal and herbicidal residues
Pesticides
Imazalil
Thiacloprid
Clothianidin
Chlordane Dichlorodiphenyltrichloroethane (DDT)
Lindane
Pentachlorophenol
Organophosphorus		Thoroughout the worldFrom agricultural activities;
Water source and soil quality of cultivating place;
From storage, transportation, covering contaminations
Hepatocellular hypertrophy and cytoplasm degeneration;
Cholestasis;
Decreased acetylcholinesterase activity;
Hepatic mitochondrial toxicity		[114,123,124,125,126]
Herbicides
Alachlor
Acetochlor
Metolachlor
Quizalofop-p-ethyl
Atrazine
Paraquat dichloride		Thoroughout the worldFrom pollutants at cultivating place;
From storage, transportation, covering contaminations		Hepatocellular enlargement and cytoplasm worsening;
Decrease and obstruction of bile flow;
Declined activity of liver acetylcholinesterase and hepatic mitochondrial dysfunction 		[127,128,129,130,131]

Share and Cite

MDPI and ACS Style

Quan, N.V.; Dang Xuan, T.; Teschke, R. Potential Hepatotoxins Found in Herbal Medicinal Products: A Systematic Review. Int. J. Mol. Sci. 2020, 21, 5011. https://doi.org/10.3390/ijms21145011

AMA Style

Quan NV, Dang Xuan T, Teschke R. Potential Hepatotoxins Found in Herbal Medicinal Products: A Systematic Review. International Journal of Molecular Sciences. 2020; 21(14):5011. https://doi.org/10.3390/ijms21145011

Chicago/Turabian Style

Quan, Nguyen Van, Tran Dang Xuan, and Rolf Teschke. 2020. "Potential Hepatotoxins Found in Herbal Medicinal Products: A Systematic Review" International Journal of Molecular Sciences 21, no. 14: 5011. https://doi.org/10.3390/ijms21145011

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop